Anthony Gulati, MD
Hematology & Oncology · Stamford, CTNPI 1508028168
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,090 of the $6,550 with a category attached, or 93.0%. 8 manufacturers reported payments, led by Janssen Scientific Affairs, LLC at 56.5% of the total. Reporting peaked in 2019 at $2,489 and has fallen 99.1% since, to $22 in 2025.
Across 13 payments — averaging $503.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Scientific Affairs, LLC$4K
- Astellas Pharma US Inc$1K
- Bayer$900
- Johnson & Johnson$585
- Foundation Medicine, Inc.$140
- Comsort, Inc$100
- plus $31 from 2 others
Across 55 payments — averaging $4173.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sumitomo Pharma America, Inc.$133K
- TG Therapeutics, Inc.$27K
- AstraZeneca$26K
- Janssen Research & Development, LLC$22K
- Genentech, Inc.$12K
- EMD Serono, Inc.$8K
- plus $155 from 1 others
What the payments were for
- Consulting fees$6,09093%
- Food & beverage$2955%
- Education$1653%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Scientific Affairs, LLC | 4 | $3,699 |
| Astellas Pharma US Inc | 3 | $1,095 |
| Bayer | 1 | $900 |
| Johnson & Johnson | 1 | $585 |
| Foundation Medicine, Inc. | 1 | $140 |
| Comsort, Inc | 1 | $100 |
| GSK | 1 | $22 |
| Coala Life Inc | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Erleada$4,284
- XTANDI$930
- Nubeqa$900
- FOUNDATIONONE$140
- FOUNDATIONONE HEME$140
- FOUNDATIONONE CDX$140
- FOUNDATIONFOCUS$140
- FOUNDATIONONE LIQUID$140
- KEYTRUDA$100
How this compares
$6,550 in reported general payments places this provider in the 65th percentile of 163 hematology & oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 106 | $1,364,009 |
| XtandiEnzalutamide | 68 | $824,121 |
| OrgovyxRelugolix | 198 | $516,541 |
| CabometyxCabozantinib S-Malate | 18 | $425,346 |
| Abiraterone Acetate | 267 | $321,156 |
| TalzennaTalazoparib Tosylate | 14 | $253,826 |
| ErleadaApalutamide | 16 | $233,916 |
| ImbruvicaIbrutinib | 12 | $222,353 |
| CalquenceAcalabrutinib Maleate | 12 | $169,695 |
| XareltoRivaroxaban | 26 | $16,982 |
| Prednisone | 171 | $636 |
| Dexamethasone | 41 | $496 |
| Hydroxyurea | 26 | $336 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerNubeqa | $900 | $1,364,009106 claims |
| Astellas Pharma US IncXtandi | $1,095 | $824,12168 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $3,699 | $321,156267 claims |
| Johnson & JohnsonErleada, Xarelto | $585 | $250,89742 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 163 hematology & oncology providers in Connecticut.
Other hematology & oncology in Stamford
- Paul WeinsteinStamford$288K
- Michael BarStamford$9K
- Amer ZeidanNew Haven$807K
- Biree AndemariamFarmington$646K
- Walid ShaibNew Haven$217K
- Madhavi GorusuHartford$207K
- Dinesh KapurNorwich$201K
- Scott HuntingtonNew Haven$163K
- Nataliya UbohaNew Haven$124K
- Michael CecchiniNew Haven$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.